JP2020526196A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526196A5 JP2020526196A5 JP2019572719A JP2019572719A JP2020526196A5 JP 2020526196 A5 JP2020526196 A5 JP 2020526196A5 JP 2019572719 A JP2019572719 A JP 2019572719A JP 2019572719 A JP2019572719 A JP 2019572719A JP 2020526196 A5 JP2020526196 A5 JP 2020526196A5
- Authority
- JP
- Japan
- Prior art keywords
- glycoprotein
- glycan
- ornithine
- putrescine
- glycans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003886 Glycoproteins Human genes 0.000 claims 32
- 108090000288 Glycoproteins Proteins 0.000 claims 32
- 238000000034 method Methods 0.000 claims 23
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims 22
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 12
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 12
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 12
- 229960003104 ornithine Drugs 0.000 claims 12
- 235000010469 Glycine max Nutrition 0.000 claims 11
- 244000068988 Glycine max Species 0.000 claims 11
- 239000005700 Putrescine Substances 0.000 claims 11
- 241000894007 species Species 0.000 claims 7
- 108010081667 aflibercept Proteins 0.000 claims 6
- 229960002833 aflibercept Drugs 0.000 claims 6
- 108010046141 rilonacept Proteins 0.000 claims 6
- 229960001886 rilonacept Drugs 0.000 claims 6
- 108010008165 Etanercept Proteins 0.000 claims 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 4
- 229960000403 etanercept Drugs 0.000 claims 4
- 239000001963 growth medium Substances 0.000 claims 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 4
- 239000006143 cell culture medium Substances 0.000 claims 3
- 102000035122 glycosylated proteins Human genes 0.000 claims 3
- 108091005608 glycosylated proteins Proteins 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010009736 Protein Hydrolysates Proteins 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 238000005251 capillar electrophoresis Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021111482A JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2024114751A JP7736872B2 (ja) | 2017-07-06 | 2024-07-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2025142351A JP2025172879A (ja) | 2017-07-06 | 2025-08-28 | 糖タンパク質を作製するための細胞培養方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762529471P | 2017-07-06 | 2017-07-06 | |
| US62/529,471 | 2017-07-06 | ||
| US201862625744P | 2018-02-02 | 2018-02-02 | |
| US62/625,744 | 2018-02-02 | ||
| PCT/US2018/040734 WO2019010191A1 (en) | 2017-07-06 | 2018-07-03 | CELL CULTURE METHOD FOR PRODUCING GLYCOPROTEIN |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021111482A Division JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A Division JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526196A JP2020526196A (ja) | 2020-08-31 |
| JP2020526196A5 true JP2020526196A5 (enExample) | 2021-08-12 |
| JP7265494B2 JP7265494B2 (ja) | 2023-04-26 |
Family
ID=64904487
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572719A Active JP7265494B2 (ja) | 2017-07-06 | 2018-07-03 | 糖タンパク質を作製するための細胞培養方法 |
| JP2021111482A Pending JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A Active JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2024114751A Active JP7736872B2 (ja) | 2017-07-06 | 2024-07-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2025142351A Pending JP2025172879A (ja) | 2017-07-06 | 2025-08-28 | 糖タンパク質を作製するための細胞培養方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021111482A Pending JP2021166537A (ja) | 2017-07-06 | 2021-07-05 | 糖タンパク質を作製するための細胞培養方法 |
| JP2023005801A Active JP7525672B2 (ja) | 2017-07-06 | 2023-01-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2024114751A Active JP7736872B2 (ja) | 2017-07-06 | 2024-07-18 | 糖タンパク質を作製するための細胞培養方法 |
| JP2025142351A Pending JP2025172879A (ja) | 2017-07-06 | 2025-08-28 | 糖タンパク質を作製するための細胞培養方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20190010531A1 (enExample) |
| EP (2) | EP3967765A1 (enExample) |
| JP (5) | JP7265494B2 (enExample) |
| KR (4) | KR20210084695A (enExample) |
| CN (3) | CN110914293B (enExample) |
| AU (4) | AU2018298039B2 (enExample) |
| BR (1) | BR112020000127A2 (enExample) |
| CA (1) | CA3067847A1 (enExample) |
| IL (2) | IL326217A (enExample) |
| MX (2) | MX2020000228A (enExample) |
| SG (1) | SG11201912548XA (enExample) |
| TW (2) | TWI910092B (enExample) |
| WO (1) | WO2019010191A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| WO2018231827A1 (en) | 2017-06-12 | 2018-12-20 | Bluefin Biomedicine, Inc. | Anti-il1rap antibodies and antibody drug conjugates |
| US10961500B1 (en) * | 2019-04-23 | 2021-03-30 | Regeneron Pharmaceuticals, Inc. | Cell culture medium for eukaryotic cells |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CN113679744B (zh) * | 2020-05-18 | 2023-12-29 | 中国人民解放军军事科学院军事医学研究院 | 寨卡病毒或其与用于免疫检查点治疗的药物在治疗胶质母细胞瘤中的用途 |
| CN114058673A (zh) * | 2021-09-15 | 2022-02-18 | 江苏先思达生物科技有限公司 | 一种脂肪肝检测试剂及其在脂肪肝检测中的应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| AT409379B (de) * | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| CN1240300C (zh) * | 2001-03-05 | 2006-02-08 | 科学与工业研究会 | 由大豆粉制备蛋白水解物的方法 |
| US6927004B2 (en) | 2002-03-08 | 2005-08-09 | Asml Netherlands B.V. | Mask for use in lithography, method of making a mask, lithographic apparatus, and device manufacturing method |
| ES2381014T3 (es) | 2004-06-08 | 2012-05-22 | Chengdu Kanghong Biotechnologies Co., Ltd. | Proteína quimérica inhibidora de la angiogénesis y el uso |
| US20060115901A1 (en) * | 2004-10-22 | 2006-06-01 | Bahram Valamehr | Method and media for single cell serum-free culture of CHO cells |
| US20060094104A1 (en) * | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
| US7642078B2 (en) * | 2005-12-28 | 2010-01-05 | Crucell Holland B.V. | Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby |
| ES2474573T3 (es) * | 2006-01-04 | 2014-07-09 | Baxter International Inc | Medio de cultivo celular sin oligop�ptidos |
| US8216575B2 (en) | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| DK2150617T3 (en) | 2007-06-04 | 2015-01-12 | Regeneron Pharma | Regions with increased expression and stability |
| US20100221823A1 (en) * | 2007-06-11 | 2010-09-02 | Amgen Inc. | Method for culturing mammalian cells to improve recombinant protein production |
| JP5588865B2 (ja) | 2007-07-31 | 2014-09-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｃｄ２０に対するヒト抗体及びその使用方法 |
| US8309088B2 (en) | 2007-08-10 | 2012-11-13 | Regeneron Pharmaceuticals, Inc. | Method of treating osteoarthritis with an antibody to NGF |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CN101603026B (zh) * | 2009-06-19 | 2011-01-19 | 华东理工大学 | 适于动物细胞产品生产的无动物来源低蛋白培养基 |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| NZ597727A (en) * | 2009-07-31 | 2013-08-30 | Baxter Int | Cell culture medium for adamts protein expression |
| CN102115728B (zh) * | 2009-12-31 | 2012-09-26 | 北京清大天一科技有限公司 | 无血清动物细胞培养基干粉、液体培养基及其制备方法 |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
| KR20130101034A (ko) * | 2010-08-31 | 2013-09-12 | 프리슬랜드 브랜즈 비브이 | 진핵 세포를 위한 배양 배지 |
| AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| MX366337B (es) | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| KR20140097245A (ko) * | 2011-10-31 | 2014-08-06 | 머크 샤프 앤드 돔 코포레이션 | 개선된 특성을 갖는 항체의 제조 방법 |
| SMT201800092T1 (it) | 2011-11-14 | 2018-03-08 | Regeneron Pharma | Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a |
| KR102063028B1 (ko) | 2012-01-23 | 2020-01-07 | 리제너론 파아마슈티컬스, 인크. | 항-ａｎｇ2 항체를 함유하는 안정화된 제형 |
| WO2013120497A1 (en) * | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| WO2013192009A1 (en) * | 2012-06-21 | 2013-12-27 | Baxter International Inc. | Virus filtration of cell culture media |
| TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| HK1206628A1 (en) * | 2012-08-02 | 2016-01-15 | Sanofi | Article of manufacture comprising aflibercept or ziv-aflibercept |
| NZ704771A (en) | 2012-08-13 | 2018-02-23 | Regeneron Pharma | Anti-pcsk9 antibodies with ph-dependent binding characteristics |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| TWI659968B (zh) | 2013-03-14 | 2019-05-21 | 再生元醫藥公司 | 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法 |
| AR095196A1 (es) * | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US20160237400A1 (en) * | 2013-03-15 | 2016-08-18 | The Jackson Laboratory | Isolation of non-embryonic stem cells and uses thereof |
| JP6404314B2 (ja) | 2013-03-15 | 2018-10-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｉｌ−３３拮抗薬とその使用法 |
| CA2908407C (en) * | 2013-05-29 | 2022-06-14 | F. Hoffmann-La Roche Ag | Quantitative control of sialylation |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| MX376230B (es) * | 2014-01-13 | 2025-03-07 | Amgen Inc | Regulación del metábolismo de ornitina para manipular el contenido de glicoformas ricas en manosa de proteínas recombinantes. |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| AU2015229591B2 (en) | 2014-03-11 | 2020-10-22 | Regeneron Pharmaceuticals, Inc. | Anti-EGFRvlll antibodies and uses thereof |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| MX2016014504A (es) | 2014-05-05 | 2017-05-23 | Regeneron Pharma | Animales c5 y c3 humanizados. |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| KR20170010003A (ko) * | 2014-05-27 | 2017-01-25 | 아카데미아 시니카 | 박테로이드 기원의 푸코시다제 및 이의 사용 방법 |
| MA40021A (fr) * | 2014-06-03 | 2015-12-10 | Lupin Ltd | Processus de culture cellulaire destiné à produire une protéine |
| EP3194441A1 (en) | 2014-09-16 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| TWI734775B (zh) * | 2016-04-26 | 2021-08-01 | 美商美國泰福生技股份有限公司 | 細胞培養基 |
-
2018
- 2018-07-03 KR KR1020217020548A patent/KR20210084695A/ko not_active Ceased
- 2018-07-03 TW TW107122944A patent/TWI910092B/zh active
- 2018-07-03 JP JP2019572719A patent/JP7265494B2/ja active Active
- 2018-07-03 KR KR1020247012715A patent/KR102782655B1/ko active Active
- 2018-07-03 KR KR1020257008109A patent/KR20250041082A/ko active Pending
- 2018-07-03 AU AU2018298039A patent/AU2018298039B2/en active Active
- 2018-07-03 CA CA3067847A patent/CA3067847A1/en active Pending
- 2018-07-03 EP EP21196848.2A patent/EP3967765A1/en not_active Withdrawn
- 2018-07-03 KR KR1020207000732A patent/KR102659791B1/ko active Active
- 2018-07-03 SG SG11201912548XA patent/SG11201912548XA/en unknown
- 2018-07-03 WO PCT/US2018/040734 patent/WO2019010191A1/en not_active Ceased
- 2018-07-03 CN CN201880045238.2A patent/CN110914293B/zh active Active
- 2018-07-03 US US16/026,539 patent/US20190010531A1/en not_active Abandoned
- 2018-07-03 EP EP18827553.1A patent/EP3649144A4/en active Pending
- 2018-07-03 IL IL326217A patent/IL326217A/en unknown
- 2018-07-03 TW TW114106933A patent/TW202526028A/zh unknown
- 2018-07-03 MX MX2020000228A patent/MX2020000228A/es unknown
- 2018-07-03 CN CN202111031466.4A patent/CN114075269A/zh active Pending
- 2018-07-03 CN CN202411053765.1A patent/CN118878651A/zh active Pending
- 2018-07-03 BR BR112020000127-9A patent/BR112020000127A2/pt unknown
-
2019
- 2019-12-18 IL IL271524A patent/IL271524A/en unknown
-
2020
- 2020-01-08 MX MX2024013233A patent/MX2024013233A/es unknown
- 2020-01-14 US US16/742,723 patent/US20200131554A1/en not_active Abandoned
- 2020-05-01 US US16/864,689 patent/US20200255880A1/en not_active Abandoned
-
2021
- 2021-07-05 JP JP2021111482A patent/JP2021166537A/ja active Pending
- 2021-08-23 US US17/409,193 patent/US20210388408A1/en not_active Abandoned
- 2021-08-23 US US17/409,158 patent/US20210388407A1/en active Pending
- 2021-09-06 AU AU2021229121A patent/AU2021229121A1/en not_active Abandoned
-
2023
- 2023-01-18 JP JP2023005801A patent/JP7525672B2/ja active Active
- 2023-05-01 AU AU2023202659A patent/AU2023202659B2/en active Active
-
2024
- 2024-07-18 JP JP2024114751A patent/JP7736872B2/ja active Active
-
2025
- 2025-04-30 AU AU2025203053A patent/AU2025203053A1/en active Pending
- 2025-08-28 JP JP2025142351A patent/JP2025172879A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hirahara et al. | Helper T‐cell differentiation and plasticity: insights from epigenetics | |
| JP2022503959A5 (enExample) | ||
| LeMessurier et al. | Influenza A virus directly modulates mouse eosinophil responses | |
| Lacruz et al. | Identification of novel candidate genes involved in mineralization of dental enamel by genome‐wide transcript profiling | |
| JP2018141797A5 (enExample) | ||
| ATE462000T1 (de) | Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin | |
| JP2009055921A5 (enExample) | ||
| RU2008126743A (ru) | Способ получения фармацевтической композиции | |
| JP2006500907A5 (enExample) | ||
| BRPI0612273A2 (pt) | anticorpo de ligaÇço a il-1 beta ou fragmento de ligaÇço a il-1 beta do mesmo, Ácido nucleico, vetor, cÉlula, animal transgÊnico, hibridoma, composiÇço, e, mÉtodos de tratamento ou prevenÇço de uma doenÇa ou doenÇa relacionada a il-1 em um mamÍfero, e de preparaÇço de um polipeptÍdeo de ligaÇço a il-1 beta maturado por afinidade | |
| RU2008126931A (ru) | Варианты неурегулина и способы их скрининга и получения | |
| EA200970263A1 (ru) | Полностью человеческая высокопродуктивная система получения усовершенствованных антител и белков | |
| RU2013152816A (ru) | АНТИТЕЛО ПРОТИВ ПРОТЕИНТИРОЗИНФОСФАТАЗЫ σ РЕЦЕПТОРНОГО ТИПА ЧЕЛОВЕКА | |
| Yamamoto et al. | Does genetic predisposition contribute to the exacerbation of COVID-19 symptoms in individuals with comorbidities and explain the huge mortality disparity between the East and the West? | |
| Sunshine et al. | Systematic functional interrogation of SARS-CoV-2 host factors using Perturb-seq | |
| RU2011142793A (ru) | Полученная из микроорганизма протеаза усовершенствованного типа, обеспечивающая свертывание молока | |
| Hayduk et al. | Cytochalasin D can improve heterologous protein productivity in adherent Chinese hamster ovary cells | |
| WO2005010023A3 (en) | Method for prediction of an epitope | |
| ATE502305T1 (de) | Verwendung von vorstufen von enkephalinen und/oder deren fragmenten in der medizinischen diagnostik | |
| RU2017134418A (ru) | Выявление аффинно-зрелых человеческих антител | |
| EA200600554A1 (ru) | Способ получения рекомбинантных белков | |
| CN110684736A (zh) | 一种基于CRISPR-Cas9编辑技术的敲除鸡Shp-2基因的细胞系及其构建方法 | |
| Palermo et al. | Old world monkeys and new age science: the evolution of nonhuman primate systems virology | |
| Bruel et al. | Epithelial induction of porcine suppressor of cytokine signaling 2 (SOCS2) gene expression in response to Entamoeba histolytica | |
| ATE445009T1 (de) | Signalpeptid zur herstellung eines polypeptids |